6th Annual Viral Hepatitis Drug Discovery & Development

In 2005, Strategic Research Institute has organized a more scientific and medical specialist agenda by focusing on an area of growing and commercial endeavor, Hepatitis B and Hepatitis C. Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated. HBV affects over 2 billion people in the world today while HCV affects approximately 4 million people each year. With this in mind, the Antiviral meeting has transformed from a broad to a more focused meeting on Viral Hepatitis in Drug Discovery & Development Summit.

You will have plenty of opportunity to participate in the excellent networking and business development opportunities at the meeting by interacting with the leading scientists and decision-makers from the pharmaceutical/biotech industry, public health, and academic communities working in the area of viral hepatitis of North America and internationally.

Hepatitis C: Virology, Biology, and Therapeutic/Preventative Targets

Michael Houghton, Ph.D.
Vice President of HCV Vaccines Research
CHIRON CORPORATION
Limiting Cellular Antiviral Defenses through Proteolytic Cleavage of Cellular Substrates by the Hepatitis C Virus NS3/4A Protease

Kui Li, M.D., Ph.D.
Assistant Professor, Department of Microbiology and Immunology
UNIVERSITY OF TEXAS MEDICAL BRANCH
RNAi-based Therapies for Viral Hepatitis

Mark A. Kay, MD, PhD
Professor, Departments of Pediatrics and Genetics
Director, Program in Human Gene Therapy
STANFORD UNIVERSITY SCHOOL OF MEDICINE

March 22 - 23, 2005

Select Pricing Option

$1,495.00 1. Standard Rate for Delegates
$695.00 2. Academic Rate